Autopsy report · NCT06901349
A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
Cause of deathFunding or business
“Study terminated for strategic business reasons”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 2
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Conditions
- Obesity; Overweight
- Interventions
- Bimagrumab; Tirzepatide; Bimagrumab Placebo; Tirzepatide Placebo
- Participants
- 0
- Sites
- 50
- Countries
- Argentina, Canada, China, Japan, United States
Trials that died the same way
- The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B
“Study terminated due to business and strategic decision” - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis
“The study was terminated due to strategic business reasons.” - A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers
“Study terminated as part of strategic considerations” - Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours
“Study terminated for business reasons” - Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.
“Study terminated due to business priorities”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.